Navega Therapeutics, Inc.
Navega Therapeutics is harnessing the precision of zinc-finger and CRISPR based epigenome regulation to enable next-generation gene therapies for chronic pain and precision pain management.
Funding history
About Navega Therapeutics, Inc.
How much funding has Navega Therapeutics, Inc. raised?
Navega Therapeutics, Inc. has raised $1.3M in total funding.
Where is Navega Therapeutics, Inc. headquartered?
Navega Therapeutics, Inc. is headquartered in San Diego, CA.
What does Navega Therapeutics, Inc. do?
Navega Therapeutics is harnessing the precision of zinc-finger and CRISPR based epigenome regulation to enable next-generation gene therapies for chronic pain and precision pain management.
What problem does Navega Therapeutics, Inc. solve?
Chronic pain currently lacks precise, targeted treatment options.
What's Navega Therapeutics, Inc.'s solution?
Navega Therapeutics develops gene therapies for chronic pain and precision pain management.
What makes Navega Therapeutics, Inc. different?
They specifically harness zinc-finger and CRISPR-based epigenome regulation, technology they position as enabling next-generation, precision gene therapies.
What makes Navega Therapeutics, Inc. notable?
Navega Therapeutics was founded in 2018 by Ana Moreno along with UC San Diego bioengineering professor Prashant Mali, developing gene therapies for chronic pain; it has received a CIRM grant to support its work.
Leadership
Related terms
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated September 3, 2026.
🏷 Embed this badge
Building or fundraising? Add this to your site to show you're listed on SoCal.Startups — the link back helps other founders and investors find you here too.
